UK Markets closed

Innate Pharma S.A. (IPHA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.3500-0.3900 (-8.23%)
As of 03:44PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close4.7400
Bid4.2700 x 800
Ask4.3200 x 800
Day's range4.2700 - 4.6900
52-week range3.0200 - 11.9500
Avg. volume1,407,937
Market cap347.967M
Beta (5Y monthly)0.11
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Motley Fool

    Here's Why Innate Pharma Stock Is Rocketing Higher Today

    Shares of Innate Pharma (NASDAQ: IPHA), a clinical-stage biotechnology company, are rocketing higher in response to successful clinical-trial data for an experimental cancer drug called monalizumab. Monalizumab is currently in a phase 2 trial called Coast, in combination with Imfinzi from AstraZeneca (NASDAQ: AZN). Imfinzi is approved to treat advanced-stage non-small cell lung cancer (NSCLC) patients with tumors that haven't grown since beginning standard first-line treatment.